Skip to main content

Table 3 Predictors of Gleason sum upgrading from biopsy to RP

From: Predicting Gleason sum upgrading from biopsy to radical prostatectomy pathology: a new nomogram and its internal validation

Variables

Univariable analysis

Multivariable analysis

OR (95% CI)

P value

OR (95% CI)

P value

Age at biopsy

0.98(0.94–1.03)

0.494

MS, presence vs absence

1.65 (0.83–3.28)

0.152

BMI

1.05 (0.95–1.15)

0.343

Interval from biopsy to RP

1.00(0.99–1.00)

0.253

PV

1.00(0.99–1.01)

0.713

Pre-biopsy PSA level

1.01(1.00–1.02)

0.009

1.02(1.00–1.03)

0.007

Pre-biopsy PSAD

1.42(1.01–2.01)

0.044

0.41(0.14–1.12)

0.522

Clinical T-stage

 T1c-2a

1.00(Reference)

-

1.00(Reference)

 T2b-2c

3.21(1.64–6.26)

0.001

4.13(1.82–7.24)

0.042

 T3a-3b

1.67(0.67–4.15)

0.272

2.39(0.86–4.85)

0.122

PI-RADS score 4–5 versus 2–3

5.57(2.53–12.27)

< 0.001

4.81(2.07–11.18)

< 0.001

Cores obtained

 12–23

1.00(Reference)

 24

0.63(0.23–1.78)

0.385

 25–30

0.42(0.10–1.72)

0.231

FPC

1.24(0.37–4.14)

0.731

GPC

5.34(1.98–14.39)

0.001

3.09(1.05–9.07)

0.040

Experience in biopsy, senior versus junior

1.04(0.59–1.85)

0.886

  1. OR odds ratio, CI confidence interval, MS metabolic syndrome, RP radical prostatectomy, BMI body mass index, PV prostate volume, PSA prostate specific antigen, PSAD PSA density, PI-RADS Prostate Imaging Reporting and Data System, FPC fraction of positive cores, GPC the greatest percentage of cancer